Objective: Evaluate nebulized tranexamic acid (TXA) as a treatment to reduce the need for an operation to control a post-tonsillectomy hemorrhage (PTH).
Methods: Based on a successful case report of a child treated with nebulized TXA for PTH in 2018, our institution began to treat PTH patients with three doses of nebulized TXA. To evaluate the outcomes of this non-invasive management, we conducted a three-year retrospective cohort study of children presenting with PTH from 2016 to 2019. Demographics, insurance, and laboratory information were collected from all pediatric tonsillectomies with and without adenoidectomy performed during the study period. Tonsillar fossae observations of bleeding and clot were documented before and after receiving TXA.
Results: The incidence of pediatric PTH at our institution during the study period was 5.4%. Fourteen out of 58 PTH patients received nebulized TXA. Receiving nebulized TXA had no adverse events and over 60% showed resolution of bleeding on exam. Receiving nebulized TXA compared to routine care decreased the need for an operation to restore hemostasis by 44%, p < 0.005. There was no significant difference in age, gender, body mass index, hemoglobin, platelet count, trainee presence, or Medicaid status between the children that received TXA and those that did not.
Conclusion: Treatment of PTH with nebulized TXA may be a safe first-line therapy to decrease the need for operative control of bleeding. This data suggests that a large clinical trial is needed to determine the efficacy of nebulized TXA to mitigate this common and potentially fatal post-operative complication.
Level Of Evidence: 4.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijporl.2021.110802 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis-A Systematic Review and Meta-Analysis.
Lung
January 2025
Department of Emergency Medicine, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation, Puducherry, India.
Background: Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes.
View Article and Find Full Text PDFAdvances in the study of nebulized tranexamic acid for pulmonary hemorrhage.
Eur J Clin Pharmacol
February 2025
Department of Cardiology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- Pulmonary hemorrhage is a serious condition that causes blood to leak into the lungs, leading to severe breathing issues, and nebulized tranexamic acid (TXA) shows promise as a treatment option due to its targeted effects and fewer side effects.
- A thorough search of multiple research databases revealed studies on nebulized TXA for pulmonary hemorrhage, including data from two randomized controlled trials, six case series, and nine case reports.
- The findings indicate that nebulized TXA effectively manages bleeding with a dosage of 500 mg/5 ml given 3-4 times daily, showing safety with minimal side effects, mainly local reactions that are easily treated.
Nebulized tranexamic acid for treatment of post-tonsillectomy bleeding: a systematic review and meta-analysis.
Eur Arch Otorhinolaryngol
October 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Hera General Hospital, Makkah, Saudi Arabia.
Article Synopsis
- The study investigates the use of nebulized tranexamic acid (TXA) for treating post-tonsillectomy bleeding (PTB), a common complication leading to emergency department visits.
- By systematically reviewing nine studies, the researchers assessed the effectiveness and safety of nebulized TXA, finding a lower reoperation rate for those treated with TXA compared to those who weren't.
- The results suggest that nebulized TXA is a safe and effective treatment for PTB, but more extensive research is needed to confirm these findings.
First Reported Case of Anaphylaxis to Nebulized Tranexamic Acid in a Pediatric Patient: A Rare but Critical Event.
Pediatr Allergy Immunol Pulmonol
July 2024
Department of Pediatrics, Ministry of Health Konya Dr Ali Kemal Belviranlı Obstetrics and Gynecology Hospital, Konya, Turkey.
Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss due to certain medical conditions. It has a low side effect profile and is safe to administer in most instances. Anaphylaxis cases due to intravenous TXA have been reported in the literature.
View Article and Find Full Text PDFTreatment of Post-Tonsillectomy Hemorrhage With Nebulized Tranexamic Acid: Initial Investigation of a Novel Therapeutic Modality.
Ann Otol Rhinol Laryngol
August 2024
Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Chicago, IL, USA.
Objectives: The use of nebulized tranexamic acid (TXA) in massive pulmonary hemorrhage is well-described. Published utilization in post-tonsillectomy bleeding (PTB) is limited to a single case. This study examines whether TXA resulted in change of operative intervention necessity and narcotic utilization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!